147 related articles for article (PubMed ID: 36835818)
1. Heart Failure Association-International Cardio-Oncology Society Risk Score Validation in HER2-Positive Breast Cancer.
Cronin M; Crowley A; Davey MG; Ryan P; Abdelshafy M; Elkoumy A; Elzomor H; Arsang-Jang S; Ganly S; Nash P; Crowley J; Sharif F; Simpkin A; Lowery A; Wijns W; Kerin M; Soliman O
J Clin Med; 2023 Feb; 12(4):. PubMed ID: 36835818
[TBL] [Abstract][Full Text] [Related]
2. Baseline cardio-oncologic risk assessment in breast cancer women and occurrence of cardiovascular events: The HFA/ICOS risk tool in real-world practice.
Tini G; Cuomo A; Battistoni A; Sarocchi M; Mercurio V; Ameri P; Volpe M; Porto I; Tocchetti CG; Spallarossa P
Int J Cardiol; 2022 Feb; 349():134-137. PubMed ID: 34848212
[TBL] [Abstract][Full Text] [Related]
3. The added value of the HFA/ICOS score in the prediction of chemotherapy-related cardiac dysfunction in breast cancer.
Di Lisi D; Madaudo C; Faro DC; Rossetto L; Triolo OF; Losi V; Galassi AR; Monte IP; Novo G
J Cardiovasc Med (Hagerstown); 2024 Mar; 25(3):218-224. PubMed ID: 38305134
[TBL] [Abstract][Full Text] [Related]
4. Incidence of cardiotoxicity and validation of the Heart Failure Association-International Cardio-Oncology Society risk stratification tool in patients treated with trastuzumab for HER2-positive early breast cancer.
Battisti NML; Andres MS; Lee KA; Ramalingam S; Nash T; Mappouridou S; Senthivel N; Asavisanu K; Obeid M; Tripodaki ES; Angelis V; Fleming E; Goode EF; John S; Rosen SD; Allen M; Stanway S; Lyon AR; Ring A
Breast Cancer Res Treat; 2021 Jul; 188(1):149-163. PubMed ID: 33818652
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular adverse events and prognosis in patients with haematologic malignancies and breast cancer receiving anticancer agents: Kurume-CREO Registry insights.
Shibata T; Nohara S; Morikawa N; Shibao K; Ito S; Shibata R; Toh U; Nagafuji K; Fukami K; Fukumoto Y
Eur J Prev Cardiol; 2023 Dec; 30(18):1941-1949. PubMed ID: 37352112
[TBL] [Abstract][Full Text] [Related]
6. The new HFA/ICOS risk assessment tool to identify patients with chronic myeloid leukaemia at high risk of cardiotoxicity.
Di Lisi D; Madaudo C; Alagna G; Santoro M; Rossetto L; Siragusa S; Novo G
ESC Heart Fail; 2022 Jun; 9(3):1914-1919. PubMed ID: 35355425
[TBL] [Abstract][Full Text] [Related]
7. Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC).
Čelutkienė J; Pudil R; López-Fernández T; Grapsa J; Nihoyannopoulos P; Bergler-Klein J; Cohen-Solal A; Farmakis D; Tocchetti CG; von Haehling S; Barberis V; Flachskampf FA; Čeponienė I; Haegler-Laube E; Suter T; Lapinskas T; Prasad S; de Boer RA; Wechalekar K; Anker MS; Iakobishvili Z; Bucciarelli-Ducci C; Schulz-Menger J; Cosyns B; Gaemperli O; Belenkov Y; Hulot JS; Galderisi M; Lancellotti P; Bax J; Marwick TH; Chioncel O; Jaarsma T; Mullens W; Piepoli M; Thum T; Heymans S; Mueller C; Moura B; Ruschitzka F; Zamorano JL; Rosano G; Coats AJS; Asteggiano R; Seferovic P; Edvardsen T; Lyon AR
Eur J Heart Fail; 2020 Sep; 22(9):1504-1524. PubMed ID: 32621569
[TBL] [Abstract][Full Text] [Related]
8. Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology.
Pudil R; Mueller C; Čelutkienė J; Henriksen PA; Lenihan D; Dent S; Barac A; Stanway S; Moslehi J; Suter TM; Ky B; Štěrba M; Cardinale D; Cohen-Solal A; Tocchetti CG; Farmakis D; Bergler-Klein J; Anker MS; Von Haehling S; Belenkov Y; Iakobishvili Z; Maack C; Ciardiello F; Ruschitzka F; Coats AJS; Seferovic P; Lainscak M; Piepoli MF; Chioncel O; Bax J; Hulot JS; Skouri H; Hägler-Laube ES; Asteggiano R; Fernandez TL; de Boer RA; Lyon AR
Eur J Heart Fail; 2020 Nov; 22(11):1966-1983. PubMed ID: 33006257
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Risk Prediction Models to Identify Cancer Therapeutics Related Cardiac Dysfunction in Women with HER2+ Breast Cancer.
Suntheralingam S; Fan CS; Calvillo-Argüelles O; Abdel-Qadir H; Amir E; Thavendiranathan P
J Clin Med; 2022 Feb; 11(3):. PubMed ID: 35160296
[TBL] [Abstract][Full Text] [Related]
10. Personalized Decision Making in Early Stage Breast Cancer: Applying Clinical Prediction Models for Anthracycline Cardiotoxicity and Breast Cancer Mortality Demonstrates Substantial Heterogeneity of Benefit-Harm Trade-off.
Upshaw JN; Ruthazer R; Miller KD; Parsons SK; Erban JK; O'Neill AM; Demissei B; Sledge G; Wagner L; Ky B; Kent DM
Clin Breast Cancer; 2019 Aug; 19(4):259-267.e1. PubMed ID: 31175052
[TBL] [Abstract][Full Text] [Related]
11. Heart failure prevention and monitoring strategies in HER2-positive breast cancer: a narrative review.
Jafari L; Akhter N
Breast Cancer Res Treat; 2021 Apr; 186(2):295-303. PubMed ID: 33481134
[TBL] [Abstract][Full Text] [Related]
12. The Framingham risk score underestimates the risk of cardiovascular events in the HER2-positive breast cancer population.
Law W; Johnson C; Rushton M; Dent S
Curr Oncol; 2017 Oct; 24(5):e348-e353. PubMed ID: 29089804
[TBL] [Abstract][Full Text] [Related]
13. Trastuzumab-induced cardiotoxicity: testing a clinical risk score in a real-world cardio-oncology population.
Rushton M; Johnson C; Dent S
Curr Oncol; 2017 Jun; 24(3):176-180. PubMed ID: 28680277
[TBL] [Abstract][Full Text] [Related]
14. Deceleration capacity of heart rate predicts trastuzumab-related cardiotoxicity in patients with HER2-positive breast cancer: A prospective observational study.
Feng Y; Qin Z; Yang Z
J Clin Pharm Ther; 2021 Feb; 46(1):93-98. PubMed ID: 32975332
[TBL] [Abstract][Full Text] [Related]
15. Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies.
Dempsey N; Rosenthal A; Dabas N; Kropotova Y; Lippman M; Bishopric NH
Breast Cancer Res Treat; 2021 Jul; 188(1):21-36. PubMed ID: 34115243
[TBL] [Abstract][Full Text] [Related]
16. An artificial intelligence approach for predicting cardiotoxicity in breast cancer patients receiving anthracycline.
Chang WT; Liu CF; Feng YH; Liao CT; Wang JJ; Chen ZC; Lee HC; Shih JY
Arch Toxicol; 2022 Oct; 96(10):2731-2737. PubMed ID: 35876889
[TBL] [Abstract][Full Text] [Related]
17. Racial disparities in the rate of cardiotoxicity of HER2-targeted therapies among women with early breast cancer.
Litvak A; Batukbhai B; Russell SD; Tsai HL; Rosner GL; Jeter SC; Armstrong D; Emens LA; Fetting J; Wolff AC; Silhy R; Stearns V; Connolly RM
Cancer; 2018 May; 124(9):1904-1911. PubMed ID: 29381193
[TBL] [Abstract][Full Text] [Related]
18. Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer.
Yu AF; Singh JC; Wang R; Liu JE; Eaton A; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
Oncologist; 2017 Jun; 22(6):642-647. PubMed ID: 28341761
[TBL] [Abstract][Full Text] [Related]
19. Cardiac safety analysis of anti-HER2-targeted therapy in early breast cancer.
Zhang L; Wang Y; Meng W; Zhao W; Tong Z
Sci Rep; 2022 Aug; 12(1):14312. PubMed ID: 35995984
[TBL] [Abstract][Full Text] [Related]
20. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
Prat A; Guarneri V; Paré L; Griguolo G; Pascual T; Dieci MV; Chic N; González-Farré B; Frassoldati A; Sanfeliu E; Cejalvo JM; Muñoz M; Bisagni G; Brasó-Maristany F; Urso L; Vidal M; Brandes AA; Adamo B; Musolino A; Miglietta F; Conte B; Oliveira M; Saura C; Pernas S; Alarcón J; Llombart-Cussac A; Cortés J; Manso L; López R; Ciruelos E; Schettini F; Villagrasa P; Carey LA; Perou CM; Piacentini F; D'Amico R; Tagliafico E; Parker JS; Conte P
Lancet Oncol; 2020 Nov; 21(11):1455-1464. PubMed ID: 33152285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
